RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $113
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the price target from $112 to $113.
RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the price target from $112 to $113.